Hutchison China MediTech Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hutchison China MediTech Limited
The cancer drug developer led by former Gilead R&D head Norbert Bischofberger will start a registrational trial for its recently acquired SYK inhibitor and the first trial for its CDK9 inhibitor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
- OTC, Consumer
- Other Names / Subsidiaries
- Hutchison Whampoa Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited